Skip to search boxSkip to navigationSkip to main content

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

  • Tibor J. Kovacsovics
    ,
  • Alice Mims
    ,
  • Mohamed E. Salama
    ,
  • Jeremy Mark Pantin
    ,
  • Narayanam Rao
    ,
  • Ken M. Kosak
*Corresponding author for this work
  • University of Utah
    ,
  • Medical University of South Carolina
    ,
  • ,
  • Porta Clinica PLLC
    ,
  • University of Georgia
    ,
  • Wake Forest University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

<p>Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20×10<sup>9</sup>/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 381-389 (9 pages)

Journal (Volume, Issue Number)

Blood Advances (Volume 2, Issue 4)

Publication milestones

  • Published - 02/27/2018

Publication status

Published - 02/27/2018

ISSN

2473-9529

Publication IDs

  • Scopus: 85056610351
  • PubMed: 29467192

Publication metrics

Metrics

SciVal
FWCI
1.55
SciVal
Author count
15
SciVal
citations
19
SciVal
Paper percentile
91
SciVal
Top percentile
10
Scopus
citations
Fractional count
1
Fractional count
0.07
Fractional count
14
Fractional count
0.93
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
55
Citation count
54
Mentions
22

Funding Details

FunderFunding number
NCI
R01CA178397